Indications › MASH / NAFLD

GLP‑1 drugs in MASH / NAFLD

Which incretin agents are being studied in MASH / NAFLD, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file

50

Active

18

Results scheduled

5

Molecules studied

9

Sponsors

35

No GLP‑1 or incretin drug is FDA-approved for MASH / NAFLD. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.

No GLP-1 or incretin drug is approved for mash / nafld, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 27 of the 50 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 23 still in early phases. 35 distinct sponsors are involved, 22 of the trials run commercially and the rest by universities and hospitals.

Molecules studied in this indication

dulaglutide · efinopegdutide · exenatide · liraglutide · mazdutide · pemvidutide · semaglutide in this indication · survodutide · tirzepatide

Results due in this indication

Trials on file

All 50 incretin trials recorded in this indication, active first.